Overview

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications. Participants will receive 26 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Biguanides
Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin, Globin Zinc
Meglitinide
Pioglitazone